MTEX vs. PYXS, BMEA, INCR, ABOS, IMUX, IKNA, MNOV, IZTC, ADAP, and IGMS
Should you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), Ikena Oncology (IKNA), MediciNova (MNOV), Invizyne Technologies (IZTC), Adaptimmune Therapeutics (ADAP), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry.
Mannatech vs. Its Competitors
Mannatech (NASDAQ:MTEX) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
13.0% of Mannatech shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Mannatech has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Pyxis Oncology has a net margin of 0.00% compared to Mannatech's net margin of -0.19%. Mannatech's return on equity of -2.56% beat Pyxis Oncology's return on equity.
In the previous week, Mannatech had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 5 mentions for Mannatech and 2 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.93 beat Mannatech's score of 0.38 indicating that Pyxis Oncology is being referred to more favorably in the news media.
Pyxis Oncology has a consensus target price of $9.00, indicating a potential upside of 733.33%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than Mannatech.
Mannatech has higher revenue and earnings than Pyxis Oncology. Mannatech is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Pyxis Oncology beats Mannatech on 8 of the 15 factors compared between the two stocks.
Get Mannatech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mannatech Competitors List
Related Companies and Tools
This page (NASDAQ:MTEX) was last updated on 7/1/2025 by MarketBeat.com Staff
Free MTEX Stock Alerts